These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 33232359)

  • 1. Clinical factors as prognostic variables among molecular subgroups of endometrial cancer.
    Kolehmainen A; Pasanen A; Tuomi T; Koivisto-Korander R; Bützow R; Loukovaara M
    PLoS One; 2020; 15(11):e0242733. PubMed ID: 33232359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
    Bosse T; Nout RA; McAlpine JN; McConechy MK; Britton H; Hussein YR; Gonzalez C; Ganesan R; Steele JC; Harrison BT; Oliva E; Vidal A; Matias-Guiu X; Abu-Rustum NR; Levine DA; Gilks CB; Soslow RA
    Am J Surg Pathol; 2018 May; 42(5):561-568. PubMed ID: 29505428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
    Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
    Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
    Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
    Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization in the prediction of disease extent in endometrial carcinoma.
    Kolehmainen AM; Pasanen AM; Koivisto-Korander RL; Bützow RC; Loukovaara MJ
    Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():478-483. PubMed ID: 33189427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.
    Proctor L; Pradhan M; Leung S; Cheng A; Lee CH; Soslow RA; Gilks CB; Talhouk A; McAlpine JM; Danielsen HE; Hoang LN
    Gynecol Oncol; 2017 Sep; 146(3):596-602. PubMed ID: 28647100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
    León-Castillo A; de Boer SM; Powell ME; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Singh N; Pollock PM; Bessette P; Fyles A; Haie-Meder C; Smit VTHBM; Edmondson RJ; Putter H; Kitchener HC; Crosbie EJ; de Bruyn M; Nout RA; Horeweg N; Creutzberg CL; Bosse T;
    J Clin Oncol; 2020 Oct; 38(29):3388-3397. PubMed ID: 32749941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential impact of clinicopathological risk factors within the 2 largest ProMisE molecular subgroups of endometrial carcinoma.
    Pasanen A; Loukovaara M; Ahvenainen T; Vahteristo P; Bützow R
    PLoS One; 2021; 16(9):e0253472. PubMed ID: 34473724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis.
    Parra-Herran C; Bassiouny D; Lerner-Ellis J; Olkhov-Mitsel E; Ismiil N; Hogen L; Vicus D; Nofech-Mozes S
    Am J Surg Pathol; 2019 Dec; 43(12):1591-1599. PubMed ID: 31335355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.
    Imboden S; Nastic D; Ghaderi M; Rydberg F; Siegenthaler F; Mueller MD; Rau TT; Epstein E; Carlson JW
    Gynecol Oncol; 2021 Aug; 162(2):394-400. PubMed ID: 34127276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
    Stelloo E; Nout RA; Osse EM; Jürgenliemk-Schulz IJ; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Nijman HW; Putter H; Bosse T; Creutzberg CL; Smit VT
    Clin Cancer Res; 2016 Aug; 22(16):4215-24. PubMed ID: 27006490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.
    Britton H; Huang L; Lum A; Leung S; Shum K; Kale M; Burleigh A; Senz J; Yang W; McConechy M; Kommoss S; Brucker S; Talhouk A; Gilks CB; McAlpine JN
    Gynecol Oncol; 2019 Jun; 153(3):487-495. PubMed ID: 30922603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer.
    Loukovaara M; Pasanen A; Bützow R
    Cancer Med; 2021 Feb; 10(3):1034-1042. PubMed ID: 33449452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
    Cosgrove CM; Tritchler DL; Cohn DE; Mutch DG; Rush CM; Lankes HA; Creasman WT; Miller DS; Ramirez NC; Geller MA; Powell MA; Backes FJ; Landrum LM; Timmers C; Suarez AA; Zaino RJ; Pearl ML; DiSilvestro PA; Lele SB; Goodfellow PJ
    Gynecol Oncol; 2018 Jan; 148(1):174-180. PubMed ID: 29132872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer.
    Raffone A; Travaglino A; Gabrielli O; Micheli M; Zuccalà V; Bitonti G; Camastra C; Gargiulo V; Insabato L; Zullo F
    Arch Gynecol Obstet; 2021 Jun; 303(6):1393-1400. PubMed ID: 33754186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome.
    Reijnen C; Küsters-Vandevelde HVN; Ligtenberg MJL; Bulten J; Oosterwegel M; Snijders MPLM; Sweegers S; de Hullu JA; Vos MC; van der Wurff AAM; van Altena AM; Eijkelenboom A; Pijnenborg JMA
    Int J Cancer; 2020 Jul; 147(2):478-489. PubMed ID: 32022266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of a one-step genomics-based molecular classifier for endometrial carcinoma in a large Chinese population.
    Kang N; Zhang X; Wang Z; Dai Y; Lu S; Su W; Gai F; Zhu C; Shen D; Wang J
    Pathol Res Pract; 2024 Feb; 254():155152. PubMed ID: 38277742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Molecularly Classified Endometrial Carcinoma.
    Loukovaara M; Pasanen A; Bützow R
    Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women.
    He D; Wang H; Dong Y; Zhang Y; Zhao J; Lv C; Zheng X; Li D; Li T
    Gynecol Oncol; 2020 Oct; 159(1):36-42. PubMed ID: 32800323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective Clinical Prognostication of Endometrial Carcinomas Based on Next-Generation Sequencing and Immunohistochemistry-Real-World Implementation and Results at a Tertiary Care Center.
    Davies KD; Smith LP; Guimaraes-Young A; Corr BR; Fisher CM; Guntupalli SR; Berning AA; Post MD; Pino D; Aisner DL; Wolsky RJ
    Int J Gynecol Pathol; 2024 Jul; 43(4):335-348. PubMed ID: 37922951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.